Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Position Statements

12. Older Adults: Standards of Medical Care in Diabetes—2020

  1. American Diabetes Association
Diabetes Care 2020 Jan; 43(Supplement 1): S152-S162. https://doi.org/10.2337/dc20-S012
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Recommendations

  • 12.1 Consider the assessment of medical, psychological, functional (self-management abilities), and social geriatric domains in older adults to provide a framework to determine targets and therapeutic approaches for diabetes management. B

  • 12.2 Screen for geriatric syndromes (i.e., polypharmacy, cognitive impairment, depression, urinary incontinence, falls, and persistent pain) in older adults as they may affect diabetes self-management and diminish quality of life. B

Diabetes is an important health condition for the aging population. Approximately one-quarter of people over the age of 65 years have diabetes and one-half of older adults have prediabetes (1), and the number of older adults living with these conditions is expected to increase rapidly in the coming decades. Diabetes management in older adults requires regular assessment of medical, psychological, functional, and social domains. Older adults with diabetes have higher rates of premature death, functional disability, accelerated muscle loss, and coexisting illnesses, such as hypertension, coronary heart disease, and stroke, than those without diabetes. Screening for diabetes complications in older adults should be individualized and periodically revisited, as the results of screening tests may impact targets and therapeutic approaches (2–4). At the same time, older adults with diabetes also are at greater risk than other older adults for several common geriatric syndromes, such as polypharmacy, cognitive impairment, depression, urinary incontinence, injurious falls, and persistent pain (5). These conditions may impact older adults’ diabetes self-management abilities and quality of life if left unaddressed (2,6,7). See Section 4 “Comprehensive Medical Evaluation and Assessment of Comorbidities” (https://doi.org/10.2337/dc20-S004) for comorbidities to consider when caring for older adults with diabetes.

The comprehensive assessment described above may provide a framework to determine targets and therapeutic approaches (8–10), including whether referral for diabetes self-management education is appropriate (when complicating factors arise or when transitions in care occur) or whether the current regimen is too complex for the patient’s self-management ability or the caregivers providing care. Particular attention should be paid to complications that can develop over short periods of time and/or would significantly impair functional status, such as visual and lower-extremity complications. Please refer to the American Diabetes Association (ADA) consensus report “Diabetes in Older Adults” for details (2).

NEUROCOGNITIVE FUNCTION

Recommendation

  • 12.3 Screening for early detection of mild cognitive impairment or dementia should be performed for adults 65 years of age or older at the initial visit and annually as appropriate. B

Older adults with diabetes are at higher risk of cognitive decline and institutionalization (11,12). The presentation of cognitive impairment ranges from subtle executive dysfunction to memory loss and overt dementia. People with diabetes have higher incidences of all-cause dementia, Alzheimer disease, and vascular dementia than people with normal glucose tolerance (13). The effects of hyperglycemia and hyperinsulinemia on the brain are areas of intense research. Poor glycemic control is associated with a decline in cognitive function (14), and longer duration of diabetes is associated with worsening cognitive function. There are ongoing studies evaluating whether preventing or delaying diabetes onset may help to maintain cognitive function in older adults. However, studies examining the effects of intensive glycemic and blood pressure control to achieve specific targets have not demonstrated a reduction in brain function decline (15,16).

Clinical trials of specific interventions—including cholinesterase inhibitors and glutamatergic antagonists—have not shown positive therapeutic benefit in maintaining or significantly improving cognitive function or in preventing cognitive decline (17). Pilot studies in patients with mild cognitive impairment evaluating the potential benefits of intranasal insulin therapy and metformin therapy provide insights for future clinical trials and mechanistic studies (18–20).

Despite the paucity of therapies to prevent or remedy cognitive decline, identifying cognitive impairment early has important implications for diabetes care. The presence of cognitive impairment can make it challenging for clinicians to help their patients reach individualized glycemic, blood pressure, and lipid targets. Cognitive dysfunction makes it difficult for patients to perform complex self-care tasks (21), such as monitoring glucose and adjusting insulin doses. It also hinders their ability to appropriately maintain the timing of meals and content of diet. When clinicians are managing patients with cognitive dysfunction, it is critical to simplify drug regimens and to facilitate and engage the appropriate support structure to assist the patient in all aspects of care.

Older adults with diabetes should be carefully screened and monitored for cognitive impairment (2) (see Table 4.1 for cognitive screening recommendations). Several simple assessment tools are available to screen for cognitive impairment (22,23), such as the Mini-Mental State Examination (24), Mini-Cog (25), and the Montreal Cognitive Assessment (26), which may help to identify patients requiring neuropsychological evaluation, particularly those in whom dementia is suspected (i.e., experiencing memory loss and decline in their basic and instrumental activities of daily living). Annual screening is indicated for adults 65 years of age or older for early detection of mild cognitive impairment or dementia (4,27). Screening for cognitive impairment should additionally be considered when a patient presents with a significant decline in clinical status due to increased problems with self-care activities, such as errors in calculating insulin dose, difficulty counting carbohydrates, skipped meals, skipped insulin doses, and difficulty recognizing, preventing, or treating hypoglycemia. People who screen positive for cognitive impairment should receive diagnostic assessment as appropriate, including referral to a behavioral health provider for formal cognitive/neuropsychological evaluation (28).

HYPOGLYCEMIA

Recommendation

  • 12.4 Hypoglycemia should be avoided in older adults with diabetes. It should be assessed and managed by adjusting glycemic targets and pharmacologic regimens. B

Older adults are at higher risk of hypoglycemia for many reasons, including insulin deficiency necessitating insulin therapy and progressive renal insufficiency (29). As described above, older adults have higher rates of unidentified cognitive impairment and dementia leading to difficulties in adhering to complex self-care activities (e.g., glucose monitoring, insulin dose adjustment, etc.). Cognitive decline has been associated with increased risk of hypoglycemia and, conversely, severe hypoglycemia has been linked to increased risk of dementia (30,31). Therefore, as discussed under recommendation 12.3, it is important to routinely screen older adults for cognitive impairment and dementia and discuss findings with the patients and their caregivers.

Patients should be monitored for hypoglycemia; glycemic targets and pharmacologic regimens may need to be adjusted to minimize the occurrence of hypoglycemic events (2). Of note, it is important to prevent hypoglycemia to reduce the risk of cognitive decline (30) and other major adverse outcomes (32). Intensive glucose control in the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes study (ACCORD-MIND) was not found to benefit brain structure or cognitive function during follow-up (15). In the Diabetes Control and Complications Trial (DCCT), no significant long-term declines in cognitive function were observed, despite participants’ relatively high rates of recurrent severe hypoglycemia (33). To achieve the appropriate balance between glycemic control and risk for hypoglycemia, it is important to carefully assess and reassess patients’ risk for worsening of glycemic control and functional decline.

TREATMENT GOALS

Recommendations

  • 12.5 Older adults who are otherwise healthy with few coexisting chronic illnesses and intact cognitive function and functional status should have lower glycemic goals (such as A1C <7.5% [58 mmol/mol]), while those with multiple coexisting chronic illnesses, cognitive impairment, or functional dependence should have less-stringent glycemic goals (such as A1C <8.0–8.5% [64–69 mmol/mol]). C

  • 12.6 Glycemic goals for some older adults might reasonably be relaxed as part of individualized care, but hyperglycemia leading to symptoms or risk of acute hyperglycemia complications should be avoided in all patients. C

  • 12.7 Screening for diabetes complications should be individualized in older adults. Particular attention should be paid to complications that would lead to functional impairment. C

  • 12.8 Treatment of hypertension to individualized target levels is indicated in most older adults. C

  • 12.9 Treatment of other cardiovascular risk factors should be individualized in older adults considering the time frame of benefit. Lipid-lowering therapy and aspirin therapy may benefit those with life expectancies at least equal to the time frame of primary prevention or secondary intervention trials. E

The care of older adults with diabetes is complicated by their clinical, cognitive, and functional heterogeneity. Some older individuals may have developed diabetes years earlier and have significant complications, others are newly diagnosed and may have had years of undiagnosed diabetes with resultant complications, and still other older adults may have truly recent-onset disease with few or no complications (34). Some older adults with diabetes have other underlying chronic conditions, substantial diabetes-related comorbidity, limited cognitive or physical functioning, or frailty (35,36). Other older individuals with diabetes have little comorbidity and are active. Life expectancies are highly variable but are often longer than clinicians realize. Providers caring for older adults with diabetes must take this heterogeneity into consideration when setting and prioritizing treatment goals (9,10) (Table 12.1). In addition, older adults with diabetes should be assessed for disease treatment and self-management knowledge, health literacy, and mathematical literacy (numeracy) at the onset of treatment. See Fig. 6.2 for patient- and disease-related factors to consider when determining individualized glycemic targets.

View this table:
  • View inline
  • View popup
Table 12.1

Framework for considering treatment goals for glycemia, blood pressure, and dyslipidemia in older adults with diabetes

A1C is used as the standard biomarker for glycemic control in all patients with diabetes but may have limitations in patients who have medical conditions that impact red blood cell turnover (see Section 2 “Classification and Diagnosis of Diabetes” https://doi.org/10.2337/dc20-S002, for additional details on the limitations of A1C) (37). Many conditions associated with increased red blood cell turnover, such as hemodialysis, recent blood loss or transfusion, or erythropoietin therapy, are commonly seen in older adults with functional limitations and can falsely increase or decrease A1C. In these instances, plasma blood glucose and fingerstick readings should be used for goal setting (Table 12.1).

Healthy Patients With Good Functional Status

There are few long-term studies in older adults demonstrating the benefits of intensive glycemic, blood pressure, and lipid control. Patients who can be expected to live long enough to reap the benefits of long-term intensive diabetes management, who have good cognitive and physical function, and who choose to do so via shared decision-making may be treated using therapeutic interventions and goals similar to those for younger adults with diabetes (Table 12.1).

As with all patients with diabetes, diabetes self-management education and ongoing diabetes self-management support are vital components of diabetes care for older adults and their caregivers. Self-management knowledge and skills should be reassessed when regimen changes are made or an individual’s functional abilities diminish. In addition, declining or impaired ability to perform diabetes self-care behaviors may be an indication that a patient needs a referral for cognitive and physical functional assessment, using age-normalized evaluation tools, as well as help establishing a support structure for diabetes care (3,28).

Patients With Complications and Reduced Functionality

For patients with advanced diabetes complications, life-limiting comorbid illnesses, or substantial cognitive or functional impairments, it is reasonable to set less intensive glycemic goals (Table 12.1). Factors to consider in individualizing glycemic goals are outlined in Fig. 6.2. These patients are less likely to benefit from reducing the risk of microvascular complications and more likely to suffer serious adverse effects from hypoglycemia. However, patients with poorly controlled diabetes may be subject to acute complications of diabetes, including dehydration, poor wound healing, and hyperglycemic hyperosmolar coma. Glycemic goals should, at a minimum, avoid these consequences.

Vulnerable Patients at the End of Life

For patients receiving palliative care and end-of-life care, the focus should be to reduce the burdens and avoid the side effects of glycemic management. Thus, when organ failure develops, several agents will have to be deintensified or discontinued. For the dying patient, most agents for type 2 diabetes may be removed (38). There is, however, no consensus for the management of type 1 diabetes in this scenario (39). See end-of-life care, below, for additional information.

Beyond Glycemic Control

Although hyperglycemia control may be important in older individuals with diabetes, greater reductions in morbidity and mortality are likely to result from control of other cardiovascular risk factors rather than from tight glycemic control alone. There is strong evidence from clinical trials of the value of treating hypertension in older adults (40,41), with treatment of hypertension to individualized target levels indicated in most. There is less evidence for lipid-lowering therapy and aspirin therapy, although the benefits of these interventions for primary prevention and secondary intervention are likely to apply to older adults whose life expectancies equal or exceed the time frames of the clinical trials.

LIFESTYLE MANAGEMENT

Recommendation

  • 12.10 Optimal nutrition and protein intake is recommended for older adults; regular exercise, including aerobic activity and resistance training, should be encouraged in all older adults who can safely engage in such activities. B

Diabetes in the aging population is associated with reduced muscle strength, poor muscle quality, and accelerated loss of muscle mass, resulting in sarcopenia (42,43). Diabetes is also recognized as an independent risk factor for frailty. Frailty is characterized by decline in physical performance and an increased risk of poor health outcomes due to physiologic vulnerability to clinical, functional, or psychosocial stressors. Inadequate nutritional intake, particularly inadequate protein intake, can increase the risk of sarcopenia and frailty in older adults. Management of frailty in diabetes includes optimal nutrition with adequate protein intake combined with an exercise program that includes aerobic and resistance training (44,45).

PHARMACOLOGIC THERAPY

Recommendations

  • 12.11 In older adults with type 2 diabetes at increased risk of hypoglycemia, medication classes with low risk of hypoglycemia are preferred. B

  • 12.12 Overtreatment of diabetes is common in older adults and should be avoided. B

  • 12.13 Deintensification (or simplification) of complex regimens is recommended to reduce the risk of hypoglycemia and polypharmacy, if it can be achieved within the individualized A1C target. B

  • 12.14 Consider costs of care and insurance coverage rules when developing treatment plans in order to reduce risk of cost-related nonadherence. B

Special care is required in prescribing and monitoring pharmacologic therapies in older adults (46). See Fig. 9.1 for general recommendations regarding glucose-lowering treatment for adults with type 2 diabetes and Table 9.1 for patient- and drug-specific factors to consider when selecting glucose-lowering agents. Cost may be an important consideration, especially as older adults tend to be on many medications and live on fixed incomes (47). Accordingly, the costs of care and insurance coverage rules should be considered when developing treatment plans to reduce the risk of cost-related nonadherence (48,49). See Tables 9.2 and 9.3 for median monthly cost in the U.S. of noninsulin glucose-lowering agents and insulin, respectively. It is important to match complexity of the treatment regimen to the self-management ability of older patients and their available social and medical support. Many older adults with diabetes struggle to maintain the frequent blood glucose testing and insulin injection regimens they previously followed, perhaps for many decades, as they develop medical conditions that may impair their ability to follow their regimen safely. Individualized glycemic goals should be established (Fig. 6.3) and periodically adjusted based on coexisting chronic illnesses, cognitive function, and functional status (2). Tight glycemic control in older adults with multiple medical conditions is considered overtreatment and is associated with an increased risk of hypoglycemia; unfortunately, overtreatment is common in clinical practice (50–54). Deintensification of regimens in patients taking noninsulin glucose-lowering medications can be achieved by either lowering the dose or discontinuing some medications, so long as the individualized glycemic target is maintained. When patients are found to have an insulin regimen with complexity beyond their self-management abilities, lowering the dose of insulin may not be adequate (55). Simplification of the insulin regimen to match an individual’s self-management abilities and their available social and medical support in these situations has been shown to reduce hypoglycemia and disease-related distress without worsening glycemic control (56–58). Fig. 12.1 depicts an algorithm that can be used to simplify the insulin regimen (56). There are now multiple studies evaluating de-intensification protocols; in general, the studies demonstrate that de-intensification is safe and possibly beneficial for older adults (59). Table 12.2 provides examples of and rationale for situations where deintensification and/or insulin regimen simplification may be appropriate in older adults.

Figure 12.1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 12.1

Algorithm to simplify insulin regimen for older patients with type 2 diabetes. eGFR, estimated glomerular filtration rate. *Basal insulins: glargine U-100 and U-300, detemir, degludec, and human NPH. **See Table 12.1. ¥Mealtime insulins: short-acting (regular human insulin) or rapid-acting (lispro, aspart, and glulisine). §Premixed insulins: 70/30, 75/25, and 50/50 products. Adapted with permission from Munshi and colleagues (56,82,83).

View this table:
  • View inline
  • View popup
Table 12.2

Considerations for treatment regimen simplification and deintensification/deprescribing in older adults with diabetes (56,82)

Metformin

Metformin is the first-line agent for older adults with type 2 diabetes. Recent studies have indicated that it may be used safely in patients with estimated glomerular filtration rate ≥30 mL/min/1.73 m2 (60). However, it is contraindicated in patients with advanced renal insufficiency and should be used with caution in patients with impaired hepatic function or congestive heart failure because of the increased risk of lactic acidosis. Metformin may be temporarily discontinued before procedures, during hospitalizations, and when acute illness may compromise renal or liver function. Additionally, metformin can cause gastrointestinal side effects and a reduction in appetite that can be problematic for some older adults. Reduction or elimination of metformin may be necessary for patients experiencing gastrointestinal side effects.

Thiazolidinediones

Thiazolidinediones, if used at all, should be used very cautiously in those with, or at risk for, congestive heart failure, osteoporosis, falls or fractures, and/or macular edema (61,62).

Insulin Secretagogues

Sulfonylureas and other insulin secretagogues are associated with hypoglycemia and should be used with caution. If used, sulfonylureas with a shorter duration of action, such as glipizide or glimepiride, are preferred. Glyburide is a longer-acting sulfonylurea and should be avoided in older adults (63).

Incretin-Based Therapies

Oral dipeptidyl peptidase 4 (DPP-4) inhibitors have few side effects and minimal risk of hypoglycemia, but their cost may be a barrier to some older patients. DPP-4 inhibitors do not increase major adverse cardiovascular outcomes (64).

Glucagon-like peptide 1 (GLP-1) receptor agonists have demonstrated cardiovascular benefits among patients with established atherosclerotic cardiovascular disease, and newer trials are expanding our understanding of their benefits in other populations (64). See Section 9 “Pharmacologic Approaches to Glycemic Treatment” (https://doi.org/10.2337/dc20-S009) for a more extensive discussion regarding the specific indications for this class. While the benefits of this class are emerging, these drugs are injectable agents (with the exception of oral semaglutide), which require visual, motor, and cognitive skills for appropriate administration. They may also be associated with nausea, vomiting, and diarrhea. Given the gastrointestinal side effects of this class, GLP-1 receptor agonists may not be preferred in older patients who are experiencing unexplained weight loss.

Sodium–Glucose Cotransporter 2 Inhibitors

Sodium–glucose cotransporter 2 inhibitors are administered orally, which may be convenient for older adults with diabetes. In patients with established atherosclerotic cardiovascular disease, these agents have shown cardiovascular benefits (64). This class of agents has also been found to be beneficial for patients with heart failure and to slow the progression of chronic kidney disease. See Section 9 “Pharmacologic Approaches to Glycemic Treatment” (https://doi.org/10.2337/dc20-S009) for a more extensive discussion regarding the indications for this class of agents. While understanding of the clinical benefits of this class is evolving, side effects such as volume depletion may be more common among older patients.

Insulin Therapy

The use of insulin therapy requires that patients or their caregivers have good visual and motor skills and cognitive ability. Insulin therapy relies on the ability of the older patient to administer insulin on their own or with the assistance of a caregiver. Insulin doses should be titrated to meet individualized glycemic targets and to avoid hypoglycemia.

Once-daily basal insulin injection therapy is associated with minimal side effects and may be a reasonable option in many older patients. Multiple daily injections of insulin may be too complex for the older patient with advanced diabetes complications, life-limiting coexisting chronic illnesses, or limited functional status. Fig. 12.1 provides a potential approach to insulin regimen simplification.

Other Factors to Consider

The needs of older adults with diabetes and their caregivers should be evaluated to construct a tailored care plan. Impaired social functioning may reduce these patients’ quality of life and increase the risk of functional dependency (7). The patient’s living situation must be considered as it may affect diabetes management and support needs. Social and instrumental support networks (e.g., adult children, caretakers) that provide instrumental or emotional support for older adults with diabetes should be included in diabetes management discussions and shared decision-making.

Older adults in assisted living facilities may not have support to administer their own medications, whereas those living in a nursing home (community living centers) may rely completely on the care plan and nursing support. Those receiving palliative care (with or without hospice) may require an approach that emphasizes comfort and symptom management, while de-emphasizing strict metabolic and blood pressure control.

Special Considerations for Older Adults with Type 1 Diabetes

Due in part to the success of modern diabetes management, patients with type 1 diabetes are living longer and the population of these patients over 65 years of age is growing (65–67). Many of the recommendations in this section regarding a comprehensive geriatric assessment and personalization of goals and treatments are directly applicable to older adults with type 1 diabetes; however, this population has unique challenges and requires distinct treatment considerations (68). Insulin is an essential life-preserving therapy for patients with type 1 diabetes, unlike for those with type 2 diabetes. In order to avoid diabetic ketoacidosis, older adults with type 1 diabetes need some form of basal insulin even when they are unable to ingest meals. Insulin may be delivered through insulin pump or injections. Continuous glucose monitoring (CGM) is approved for use by Medicare and can play a critical role in improving A1C, reducing glycemic variability, and reducing risk of hypoglycemia (69) (see Section 7 “Diabetes Technology,” https://doi.org/10.2337/dc20-S007, and section 9 “Pharmacologic Approaches to Glycemic Treatment,” https://doi.org/10.2337/dc20-S009). In the older patient with type 1 diabetes, administration of insulin may become more difficult as complications, cognitive impairment, and functional impairment arise. This increases the importance of caregivers in the lives of these patients. Many older patients with type 1 diabetes require placement in long-term care (LTC) settings (i.e., nursing homes and skilled nursing facilities) and, unfortunately, these patients encounter providers that are unfamiliar with insulin pumps or CGM. Some providers may be unaware of the distinction between type 1 and type 2 diabetes. In these instances, the patient or the patient’s family may be more familiar with diabetes management than the providers. Education of relevant support staff and providers in rehabilitation and LTC settings regarding insulin dosing and use of pumps and CGM is recommended as part of general diabetes education (see recommendations 12.15 and 12.16).

TREATMENT IN SKILLED NURSING FACILITIES AND NURSING HOMES

Recommendations

  • 12.15 Consider diabetes education for the staff of long-term care and rehabilitation facilities to improve the management of older adults with diabetes. E

  • 12.16 Patients with diabetes residing in long-term care facilities need careful assessment to establish individualized glycemic goals and to make appropriate choices of glucose-lowering agents based on their clinical and functional status. E

Management of diabetes in the LTC setting is unique. Individualization of health care is important in all patients; however, practical guidance is needed for medical providers as well as the LTC staff and caregivers (70). Training should include diabetes detection and institutional quality assessment. LTC facilities should develop their own policies and procedures for prevention and management of hypoglycemia.

Resources

Staff of LTC facilities should receive appropriate diabetes education to improve the management of older adults with diabetes. Treatments for each patient should be individualized. Special management considerations include the need to avoid both hypoglycemia and the complications of hyperglycemia (2,71). For more information, see the ADA position statement “Management of Diabetes in Long-term Care and Skilled Nursing Facilities” (70).

Nutritional Considerations

An older adult residing in an LTC facility may have irregular and unpredictable meal consumption, undernutrition, anorexia, and impaired swallowing. Furthermore, therapeutic diets may inadvertently lead to decreased food intake and contribute to unintentional weight loss and undernutrition. Diets tailored to a patient’s culture, preferences, and personal goals may increase quality of life, satisfaction with meals, and nutrition status (72). It may be helpful to give insulin after meals to ensure that the dose is appropriate for the amount of carbohydrate the patient consumed in the meal.

Hypoglycemia

Older adults with diabetes in LTC are especially vulnerable to hypoglycemia. They have a disproportionately high number of clinical complications and comorbidities that can increase hypoglycemia risk: impaired cognitive and renal function, slowed hormonal regulation and counterregulation, suboptimal hydration, variable appetite and nutritional intake, polypharmacy, and slowed intestinal absorption (73). Oral agents may achieve similar glycemic outcomes in LTC populations as basal insulin (50,74).

Another consideration for the LTC setting is that, unlike in the hospital setting, medical providers are not required to evaluate the patients daily. According to federal guidelines, assessments should be done at least every 30 days for the first 90 days after admission and then at least once every 60 days. Although in practice the patients may actually be seen more frequently, the concern is that patients may have uncontrolled glucose levels or wide excursions without the practitioner being notified. Providers may make adjustments to treatment regimens by telephone, fax, or in person directly at the LTC facilities provided they are given timely notification of blood glucose management issues from a standardized alert system.

The following alert strategy could be considered:

  1. Call provider immediately in cases of low blood glucose levels (<70 mg/dL [3.9 mmol/L]).

  2. Call as soon as possible when a) glucose values are 70–100 mg/dL (3.9 and 5.6 mmol/L) (regimen may need to be adjusted), b) glucose values are >250 mg/dL (13.9 mmol/L) within a 24-h period, c) glucose values are >300 mg/dL (16.7 mmol/L) over 2 consecutive days, d) any reading is too high for the glucometer, or e) the patient is sick, with vomiting, symptomatic hyperglycemia, or poor oral intake.

END-OF-LIFE CARE

Recommendations

  • 12.17 When palliative care is needed in older adults with diabetes, providers should initiate conversations regarding the goals and intensity of care. Strict glucose and blood pressure control may not be necessary E, and reduction of therapy may be appropriate. Similarly, the intensity of lipid management can be relaxed, and withdrawal of lipid-lowering therapy may be appropriate. A

  • 12.18 Overall comfort, prevention of distressing symptoms, and preservation of quality of life and dignity are primary goals for diabetes management at the end of life. C

The management of the older adult at the end of life receiving palliative medicine or hospice care is a unique situation. Overall, palliative medicine promotes comfort, symptom control and prevention (pain, hypoglycemia, hyperglycemia, and dehydration), and preservation of dignity and quality of life in patients with limited life expectancy (71,75). In the setting of palliative care, providers should initiate conversations regarding the goals and intensity of diabetes care; strict glucose and blood pressure control may not be consistent with achieving comfort and quality of life. In a multicenter trial, withdrawal of statins among patients in palliative care has been found to improve quality of life, while similar evidence for glucose and blood pressure control are not yet available (76–78). A patient has the right to refuse testing and treatment, whereas providers may consider withdrawing treatment and limiting diagnostic testing, including a reduction in the frequency of fingerstick testing (79,80). Glucose targets should aim to prevent hypoglycemia and hyperglycemia. Treatment interventions need to be mindful of quality of life. Careful monitoring of oral intake is warranted. The decision process may need to involve the patient, family, and caregivers, leading to a care plan that is both convenient and effective for the goals of care (81). The pharmacologic therapy may include oral agents as first line, followed by a simplified insulin regimen. If needed, basal insulin can be implemented, accompanied by oral agents and without rapid-acting insulin. Agents that can cause gastrointestinal symptoms such as nausea or excess weight loss may not be good choices in this setting. As symptoms progress, some agents may be slowly tapered and discontinued.

Different patient categories have been proposed for diabetes management in those with advanced disease (39).

  1. A stable patient: Continue with the patient’s previous regimen, with a focus on the prevention of hypoglycemia and the management of hyperglycemia using blood glucose testing, keeping levels below the renal threshold of glucose. There is very little role for A1C monitoring and lowering.

  2. A patient with organ failure: Preventing hypoglycemia is of greater significance. Dehydration must be prevented and treated. In people with type 1 diabetes, insulin administration may be reduced as the oral intake of food decreases but should not be stopped. For those with type 2 diabetes, agents that may cause hypoglycemia should be reduced in dose. The main goal is to avoid hypoglycemia, allowing for glucose values in the upper level of the desired target range.

  3. A dying patient: For patients with type 2 diabetes, the discontinuation of all medications may be a reasonable approach, as patients are unlikely to have any oral intake. In patients with type 1 diabetes, there is no consensus, but a small amount of basal insulin may maintain glucose levels and prevent acute hyperglycemic complications.

Footnotes

  • Suggested citation: American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S152-S162

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. National Institute of Diabetes and Digestive and Kidney Diseases
    . Diabetes in America, 3rd edition, 2018. Accessed 27 August 2019. Available from https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition
  2. ↵
    1. Kirkman MS,
    2. Briscoe VJ,
    3. Clark N, et al
    . Diabetes in older adults. Diabetes Care 2012;35:2650–2664
    OpenUrlFREE Full Text
  3. ↵
    1. Young-Hyman D,
    2. de Groot M,
    3. Hill-Briggs F,
    4. Gonzalez JS,
    5. Hood K,
    6. Peyrot M
    . Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
    OpenUrlFREE Full Text
  4. ↵
    1. Institute of Medicine of the National Academies
    . Cognitive Aging: Progress in Understanding and Opportunities for Action, 2015. Accessed 31 October 2019. Available from http://nationalacademies.org/hmd/Reports/2015/Cognitive-Aging.aspx
  5. ↵
    1. Kimbro LB,
    2. Mangione CM,
    3. Steers WN, et al
    . Depression and all-cause mortality in persons with diabetes mellitus: are older adults at higher risk? Results from the Translating Research Into Action for Diabetes Study. J Am Geriatr Soc 2014;62:1017–1022
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sudore RL,
    2. Karter AJ,
    3. Huang ES, et al
    . Symptom burden of adults with type 2 diabetes across the disease course: diabetes & aging study. J Gen Intern Med 2012;27:1674–1681
    OpenUrlCrossRefPubMed
  7. ↵
    1. Laiteerapong N,
    2. Karter AJ,
    3. Liu JY, et al
    . Correlates of quality of life in older adults with diabetes: the Diabetes & Aging Study. Diabetes Care 2011;34:1749–1753
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. McClintock MK,
    2. Dale W,
    3. Laumann EO,
    4. Waite L
    . Empirical redefinition of comprehensive health and well-being in the older adults of the United States. Proc Natl Acad Sci U S A 2016;113:E3071–3080
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Laiteerapong N,
    2. Iveniuk J,
    3. John PM,
    4. Laumann EO,
    5. Huang ES
    . Classification of older adults who have diabetes by comorbid conditions, United States, 2005–2006. Prev Chronic Dis 2012;9:E100
    OpenUrlPubMed
  10. ↵
    1. Blaum C,
    2. Cigolle CT,
    3. Boyd C, et al
    . Clinical complexity in middle-aged and older adults with diabetes: the Health and Retirement Study. Med Care 2010;48:327–334
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Cukierman T,
    2. Gerstein HC,
    3. Williamson JD
    . Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 2005;48:2460–2469
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Roberts RO,
    2. Knopman DS,
    3. Przybelski SA, et al
    . Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 2014;82:1132–1141
    OpenUrlCrossRefPubMed
  13. ↵
    1. Xu WL,
    2. von Strauss E,
    3. Qiu CX,
    4. Winblad B,
    5. Fratiglioni L
    . Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia 2009;52:1031–1039
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Yaffe K,
    2. Falvey C,
    3. Hamilton N, et al
    . Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012;69:1170–1175
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Launer LJ,
    2. Miller ME,
    3. Williamson JD, et al.; ACCORD MIND investigators
    . Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011;10:969–977
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Murray AM,
    2. Hsu F-C,
    3. Williamson JD, et al.; Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators
    . ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia 2017;60:69–80
    OpenUrl
  17. ↵
    1. Ghezzi L,
    2. Scarpini E,
    3. Galimberti D
    . Disease-modifying drugs in Alzheimer’s disease. Drug Des Devel Ther 2013;7:1471–1478
    OpenUrlPubMed
  18. ↵
    1. Craft S,
    2. Baker LD,
    3. Montine TJ, et al
    . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29–38
    OpenUrlCrossRefPubMedWeb of Science
    1. Freiherr J,
    2. Hallschmid M,
    3. Frey WH 2nd, et al
    . Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs 2013;27:505–514
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Alagiakrishnan K,
    2. Sankaralingam S,
    3. Ghosh M,
    4. Mereu L,
    5. Senior P
    . Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discov Med 2013;16:277–286
    OpenUrlPubMed
  20. ↵
    1. Tomlin A,
    2. Sinclair A
    . The influence of cognition on self-management of type 2 diabetes in older people. Psychol Res Behav Manag 2016;9:7–20
    OpenUrlPubMed
  21. ↵
    1. National Institute on Aging
    . Assessing cognitive impairment in older patients. Accessed 27 August 2019. Available from https://www.nia.nih.gov/health/assessing-cognitive-impairment-older-patients
  22. ↵
    1. Alzheimer’s Association
    . Cognitive assessment Accessed 27 August 2019. Available from https://alz.org/professionals/healthcare-professionals/cognitive-assessment
  23. ↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR
    . “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Borson S,
    2. Scanlan JM,
    3. Chen P,
    4. Ganguli M
    . The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451–1454
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Nasreddine ZS,
    2. Phillips NA,
    3. Bédirian V, et al
    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Moreno G,
    2. Mangione CM,
    3. Kimbro L,
    4. Vaisberg E; American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus
    . Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J Am Geriatr Soc 2013;61:2020–2026
    OpenUrlCrossRefPubMed
  27. ↵
    1. American Psychological Association
    . Guidelines for the evaluation of dementia and age-related cognitive change. Accessed 31 October 2019. Available from http://www.apa.org/practice/guidelines/dementia.aspx
  28. ↵
    1. Lee AK,
    2. Lee CJ,
    3. Huang ES,
    4. Sharrett AR,
    5. Coresh J,
    6. Selvin E
    . Risk factors for severe hypoglycemia in black and white adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2017;40:1661–1667
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Feinkohl I,
    2. Aung PP,
    3. Keller M, et al.; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators
    . Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2014;37:507–515
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Lee AK,
    2. Rawlings AM,
    3. Lee CJ, et al
    . Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia 2018;61:1956–1965
    OpenUrl
  31. ↵
    1. Lee AK,
    2. Warren B,
    3. Lee CJ, et al
    . The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 2018;41:104–111
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Jacobson AM,
    2. Musen G,
    3. Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group
    . Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842–1852
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Selvin E,
    2. Coresh J,
    3. Brancati FL
    . The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 2006;29:2415–2419
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Bandeen-Roche K,
    2. Seplaki CL,
    3. Huang J, et al
    . Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci 2015;70:1427–1434
    OpenUrlCrossRefPubMed
  35. ↵
    1. Kalyani RR,
    2. Tian J,
    3. Xue Q-L, et al
    . Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc 2012;60:1701–1707
    OpenUrlCrossRefPubMed
  36. ↵
    1. NGSP
    . Factors that interfere with HbA1c test results. Accessed 31 October 2019. Available from http://www.ngsp.org/factors.asp
  37. ↵
    1. Sinclair A,
    2. Dunning T,
    3. Colagiuri S
    . IDF Global Guideline For Managing Older People With Type 2 Diabetes. Brussels, Belgium, International Diabetes Federation, 2013
  38. ↵
    1. Angelo M,
    2. Ruchalski C,
    3. Sproge BJ
    . An approach to diabetes mellitus in hospice and palliative medicine. J Palliat Med 2011;14:83–87
    OpenUrlCrossRefPubMed
  39. ↵
    1. Beckett NS,
    2. Peters R,
    3. Fletcher AE, et al.; HYVET Study Group
    . Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–1898
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. de Boer IH,
    2. Bangalore S,
    3. Benetos A, et al
    . Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 2017;40:1273–1284
    OpenUrlFREE Full Text
  41. ↵
    1. Park SW,
    2. Goodpaster BH,
    3. Strotmeyer ES, et al
    . Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006;55:1813–1818
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Park SW,
    2. Goodpaster BH,
    3. Strotmeyer ES, et al.; Health, Aging, and Body Composition Study
    . Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the Health, Aging, and Body Composition Study. Diabetes Care 2007;30:1507–1512
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Villareal DT,
    2. Chode S,
    3. Parimi N, et al
    . Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011;364:1218–1229
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Villareal DT,
    2. Aguirre L,
    3. Gurney AB, et al
    . Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med 2017;376:1943–1955
    OpenUrl
  45. ↵
    1. Valencia WM,
    2. Florez H
    . Pharmacological treatment of diabetes in older people. Diabetes Obes Metab 2014;16:1192–1203
    OpenUrlCrossRefPubMed
  46. ↵
    1. Zhang JX,
    2. Bhaumik D,
    3. Huang ES,
    4. Meltzer DO
    . Change in insurance status and cost-related medication non-adherence among older U.S. adults with diabetes from 2010 to 2014. J Health Med Econ 2018;4:7
    OpenUrl
  47. ↵
    1. Schmittdiel JA,
    2. Steers N,
    3. Duru OK, et al
    . Patient-provider communication regarding drug costs in Medicare Part D beneficiaries with diabetes: a TRIAD Study. BMC Health Serv Res 2010;10:164
    OpenUrlCrossRefPubMed
  48. ↵
    1. Patel MR,
    2. Resnicow K,
    3. Lang I,
    4. Kraus K,
    5. Heisler M
    . Solutions to address diabetes-related financial burden and cost-related nonadherence: results from a pilot study. Health Educ Behav 2018;45:101–111
    OpenUrl
  49. ↵
    1. Andreassen LM,
    2. Sandberg S,
    3. Kristensen GBB,
    4. Sølvik UØ,
    5. Kjome RLS
    . Nursing home patients with diabetes: prevalence, drug treatment and glycemic control. Diabetes Res Clin Pract 2014;105:102–109
    OpenUrl
    1. Lipska KJ,
    2. Ross JS,
    3. Miao Y,
    4. Shah ND,
    5. Lee SJ,
    6. Steinman MA
    . Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175:356–362
    OpenUrl
    1. Thorpe CT,
    2. Gellad WF,
    3. Good CB, et al
    . Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care 2015;38:588–595
    OpenUrlAbstract/FREE Full Text
    1. McAlister FA,
    2. Youngson E,
    3. Eurich DT
    . Treatment deintensification is uncommon in adults with type 2 diabetes mellitus: a retrospective cohort study. Circ Cardiovasc Qual Outcomes 2017;10:e003514
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Arnold SV,
    2. Lipska KJ,
    3. Wang J,
    4. Seman L,
    5. Mehta SN,
    6. Kosiborod M
    . Use of intensive glycemic management in older adults with diabetes mellitus. J Am Geriatr Soc 2018;66:1190–1194
    OpenUrl
  51. ↵
    1. Weiner JZ,
    2. Gopalan A,
    3. Mishra P, et al
    . use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes. JAMA Intern Med. 23 September 2019 [Epub ahead of print]. DOI: 10.1001/jamainternmed.2019.3759
  52. ↵
    1. Munshi MN,
    2. Slyne C,
    3. Segal AR,
    4. Saul N,
    5. Lyons C,
    6. Weinger K
    . Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med 2016;176:1023–1025
    OpenUrl
    1. Sussman JB,
    2. Kerr EA,
    3. Saini SD, et al
    . Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med 2015;175:1942–1949
    OpenUrl
  53. ↵
    1. Abdelhafiz AH,
    2. Sinclair AJ
    . Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complications 2018;32:444–450
    OpenUrl
  54. ↵
    1. Seidu S,
    2. Kunutsor SK,
    3. Topsever P,
    4. Hambling CE,
    5. Cos FX,
    6. Khunti K
    . Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes Metab 2019;21:1668–1679
    OpenUrl
  55. ↵
    1. Inzucchi SE,
    2. Lipska KJ,
    3. Mayo H,
    4. Bailey CJ,
    5. McGuire DK
    . Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–2675
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    1. Schwartz AV,
    2. Chen H,
    3. Ambrosius WT, et al
    . Effects of TZD use and discontinuation on fracture rates in ACCORD bone study. J Clin Endocrinol Metab 2015;100:4059–4066
    OpenUrl
  57. ↵
    1. Billington EO,
    2. Grey A,
    3. Bolland MJ
    . The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015;58:2238–2246
    OpenUrl
  58. ↵
    1. American Geriatrics Society 2015 Beers Criteria Update Expert Panel
    . American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–2246
    OpenUrlCrossRefPubMed
  59. ↵
    1. Davies MJ,
    2. D’Alessio DA,
    3. Fradkin J, et al
    . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Livingstone SJ,
    2. Levin D,
    3. Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry
    . Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37–44
    OpenUrlCrossRefPubMed
    1. Miller RG,
    2. Secrest AM,
    3. Sharma RK,
    4. Songer TJ,
    5. Orchard TJ
    . Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012;61:2987–2992
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Bullard KM,
    2. Cowie CC,
    3. Lessem SE, et al
    . Prevalence of diagnosed diabetes in adults by diabetes type—United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:359–361
    OpenUrl
  62. ↵
    1. Heise T,
    2. Nosek L,
    3. Rønn BB, et al
    . Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614–1620
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Ruedy KJ,
    2. Parkin CG,
    3. Riddlesworth TD,
    4. Graham C; DIAMOND Study Group
    . Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol 2017;11:1138–1146
    OpenUrl
  64. ↵
    1. Munshi MN,
    2. Florez H,
    3. Huang ES, et al
    . Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American Diabetes Association. Diabetes Care 2016;39:308–318
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Sinclair A,
    2. Morley JE,
    3. Rodriguez-Mañas L, et al
    . Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497–502
    OpenUrlCrossRefPubMed
  66. ↵
    1. Dorner B,
    2. Friedrich EK,
    3. Posthauer ME
    . Practice paper of the American Dietetic Association: individualized nutrition approaches for older adults in health care communities. J Am Diet Assoc 2010;110:1554–1563
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Migdal A,
    2. Yarandi SS,
    3. Smiley D,
    4. Umpierrez GE
    . Update on diabetes in the elderly and in nursing home residents. J Am Med Dir Assoc 2011;12:627–632.e2
    OpenUrlCrossRefPubMed
  68. ↵
    1. Pasquel FJ,
    2. Powell W,
    3. Peng L, et al
    . A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities. BMJ Open Diabetes Res Care 2015;3:e000104
    OpenUrlPubMed
  69. ↵
    1. Quinn K,
    2. Hudson P,
    3. Dunning T
    . Diabetes management in patients receiving palliative care. J Pain Symptom Manage 2006;32:275–286
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Kutner JS,
    2. Blatchford PJ,
    3. Taylor DH Jr, et al
    . Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015;175:691–700
    OpenUrl
    1. Dunning T,
    2. Martin P
    . Palliative and end of life care of people with diabetes: issues, challenges and strategies. Diabetes Res Clin Pract 2018;143:454–463
    OpenUrl
  71. ↵
    1. Bouça-Machado R,
    2. Rosário M,
    3. Alarcão J,
    4. Correia-Guedes L,
    5. Abreu D,
    6. Ferreira JJ
    . Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. BMC Palliat Care 2017;16:10
    OpenUrl
  72. ↵
    1. Ford-Dunn S,
    2. Smith A,
    3. Quin J
    . Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med 2006;20:197–203
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Petrillo LA,
    2. Gan S,
    3. Jing B,
    4. Lang-Brown S,
    5. Boscardin WJ,
    6. Lee SJ
    . Hypoglycemia in hospice patients with type 2 diabetes in a national sample of nursing homes. JAMA Intern Med 2018;178:713–715
    OpenUrl
  74. ↵
    1. Mallery LH,
    2. Ransom T,
    3. Steeves B,
    4. Cook B,
    5. Dunbar P,
    6. Moorhouse P
    . Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program. J Am Med Dir Assoc 2013;14:801–808
    OpenUrlCrossRefPubMed
  75. ↵
    1. Munshi MN,
    2. Slyne C,
    3. Segal AR,
    4. Saul N,
    5. Lyons C,
    6. Weinger K
    . Liberating A1C goals in older adults may not protect against the risk of hypoglycemia. J Diabetes Complications 2017;31:1197–1199
    OpenUrlPubMed
  76. ↵
    1. Leung E,
    2. Wongrakpanich S,
    3. Munshi MN
    . Diabetes management in the elderly. Diabetes Spectr 2018;31:245–253
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes Care: 43 (Supplement 1)

In this Issue

January 2020, 43(Supplement 1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Standards of Care (PDF)
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
12. Older Adults: Standards of Medical Care in Diabetes—2020
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
12. Older Adults: Standards of Medical Care in Diabetes—2020
American Diabetes Association
Diabetes Care Jan 2020, 43 (Supplement 1) S152-S162; DOI: 10.2337/dc20-S012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

12. Older Adults: Standards of Medical Care in Diabetes—2020
American Diabetes Association
Diabetes Care Jan 2020, 43 (Supplement 1) S152-S162; DOI: 10.2337/dc20-S012
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • NEUROCOGNITIVE FUNCTION
    • HYPOGLYCEMIA
    • TREATMENT GOALS
    • LIFESTYLE MANAGEMENT
    • PHARMACOLOGIC THERAPY
    • Special Considerations for Older Adults with Type 1 Diabetes
    • TREATMENT IN SKILLED NURSING FACILITIES AND NURSING HOMES
    • END-OF-LIFE CARE
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
  • 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
  • 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes—2020
Show more Position Statements

Similar Articles

Subjects

  • Epidemiology-Cardiovascular Disease

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.